Management of COPD in the UK primary-care setting: An analysis of real life prescribing patterns

International Journal of COPD

Volumn 9, Issue , 2014, Pages 889-905

  Price, David ^a   West, Daniel ^b   Brusselle, Guy ^c,d   Gruffydd Jones, Kevin ^e   Jones, Rupert ^f   Miravitlles, Marc ^g   Rossi, Andrea ^h   Hutton, Catherine ^b   Ashton, Valerie L ^b   Stewart, Rebecca ^b   Bichel, Katsiaryna ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Research in Real Life Ltd   (United Kingdom)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Box Surgery ^*  (United Kingdom)

^f PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h University and General Hospital   (Italy)

Author keywords

Bronchodilators; COPD; Inhaled corticosteroids; Prescribing patterns; UK primary care setting

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; SHORT ACTING DRUG;

ADULT; AGED; AIRFLOW; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; FEMALE; FORCED EXPIRATORY VOLUME; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SPIROMETRY; UNITED KINGDOM; CLINICAL PRACTICE; DRUG COMBINATION; DRUG EFFECTS; DRUG USE; FACTUAL DATABASE; INHALATIONAL DRUG ADMINISTRATION; LUNG; NATIONAL HEALTH SERVICE; PATHOPHYSIOLOGY; PRESCRIPTION; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; TRENDS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; BRONCHODILATOR AGENTS; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; GREAT BRITAIN; GUIDELINE ADHERENCE; HUMANS; LUNG; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPIROMETRY; STATE MEDICINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84906868882     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S62750     Document Type: Article

References (54)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2014. Global Initiative for Chronic Obstructive Lung Disease; 2014. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf. Accessed June 18, 2014.
2. National Institute for Health and Care Excellence. NICE Guidelines [CG101]: Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (Partial Update). London: National Institute for Health and Care Excellence; 2010. Available from: http://www.nice.org.uk/guidance/CG101. Accessed June 18, 2014.
3. Cazzola M, Matera MG. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. Chest. 2004;125(1):9-11.
4. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102(11):1511-1520.
5. Van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med. 2010;104(7):995-1004.
6. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67(9):781-788.
7. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484-1494.
8. Antón E. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev Respir Med. 2013;7(Suppl 2):25-32.
9. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J. 2013;22(1):117-121.
10. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J. 2009;34(1):10-12.
11. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34(1):13-16.
12. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92-100.
13. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.
14. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641-647.
15. Suissa S. Author's response to letter on number needed to treat in COPD: exacerbations versus pneumonias. Thorax. 2013;68(9):882-883.
16. Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest. 2013;143(4):1018-1024.
17. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106(7):989-997.
18. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011;27(7):1425-1429.
19. Jebrak G. [COPD routine management in France: are guidelines used in clinical practice?]. Rev Mal Respir. 2010;27(1):11-18. French [with English abstract].
20. Jochmann A, Neubauer F, Miedinger D, et al. General practitioners' adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. Epub April 21, 2010.
21. Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res. 2008;9:62.
22. Lucas AE, Smeenk FW, Smeele IJ, van Schayck CP. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam Pract. 2008;25(2):86-91.
23. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2007). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated December 2007. Global Initiative for Chronic Obstructive Lung Disease; 2007. Available from: http://www.goldcopd.org/uploads/users/files/GOLDReport07_0108.pdf. Accessed June 18, 2014.
24. British Medical Association. 2014/15 General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF). London: British Medical Association; 2014. Available from: http://bma.org.uk/practical-support-at-work/contracts/independent-contractors/qof-guidance. Accessed June 18, 2014.
25. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-654.
26. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2013). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2013. Global Initiative for Chronic Obstructive Lung Disease; 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed June 18, 2014.
27. Hill SC, Miller GE, Sing M. Adults with diagnosed and untreated diabetes: who are they? How can we reach them? J Health Care Poor Underserved. 2011;22(4):1221-1238.
28. Avasarala JR, O'Donovan CA, Roach SE, Camacho F, Feldman SR. Analysis of NAMCS data for multiple sclerosis, 1998-2004. BMC Med. 2007;5:6.
29. Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens. 2001;14(7 Pt 2):231S-236S.
30. Harris Interactive. Many Who Suffer From Multiple Sclerosis (MS) Are Not Getting Treatment They Could Benefit From. 2001. Available from: http://www.mult-sclerosis.org/news/May2001/HarrisPollPwMSundertreated.html. Accessed June 18, 2014.
31. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med. 2007;167(22):2431-2436.
32. Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:493-501.
33. Small M, Broomfield S, Higgins V. Quantification and treatment patterns of real-world patients classified by the GOLD 2011 strategy. Poster presented at: 22nd Annual Congress of the European Respiratory Society; September 1-5; 2012; Vienna, Austria.
34. Decramer M, Bartsch P, Pauwels R, Yernault JC. Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis. 2003;59(1):62-80.
35. Glaab T, Banik N, Rutschmann OT, Wencker M. National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD. 2006;3(3):141-148.
36. Miravitlles M, Brosa M, Velasco M, et al. An economic analysis of pharmacological treatment of COPD in Spain. Respir Med. 2009;103(5): 714-721.
37. Miravitlles M, Andreu I, Romero Y, Sitjar S, Altés A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract. 2012;62(595):e68-e75.
38. Perez X, Wisnivesky JP, Lurslurchachai L, Kleinman LC, Kronish IM. Barriers to adherence to COPD guidelines among primary care providers. Respir Med. 2012;106(3):374-381.
39. Salinas GD, Williamson JC, Kalhan R, et al. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis. 2011;6:171-179.
40. Pearson M, Ayres JG, Sarno M, Massey D, Price D. Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management REassessment) programme 1997-2001. Int J Chron Obstruct Pulmon Dis. 2006;1(4):435-443.
41. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids - implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221.
42. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399-404.
43. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217-224.
44. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122(1):47-55.
45. Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med. 2004;3(3):173-181.
46. Wilson I. Depression in the patient with COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):61-64.
47. Agusti A, Hurd S, Jones P, et al. FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J. 2013;42(5):1391-1401.
48. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008;63(5):402-407.
49. Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573-581.
50. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009;374(9691): 721-732.
51. Haughney J, Gruffydd-Jones K, Roberts J, Lee AJ, Hardwell A, McGarvey L. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J. 2014;43(4):993-1002.
52. Jones RC, Price D, Ryan D, et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014;2(4): 267-276.
53. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Updated 2014. Global Initiative for Chronic Obstructive Lung Disease; 2014. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014.pdf. Accessed June 18, 2014.
54. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-654.